Analysts’ Viewpoint
Rise in environmental irritants and increase in awareness about the severe effects of pediatric asthma are contributing to the global pediatric asthma treatment market growth. Various companies are obtaining FDA approvals for drugs used in the treatment of pediatric asthma.
Leading companies are arranging educative programs for children as well as healthcare professionals regarding the correct usage of inhalers through digital platforms. Rise in participation of several large organizations in spreading knowledge about disease control measures and available treatments for asthma is augmenting market statistics.
Pediatric asthma treatment is a medical approach for managing asthma symptoms in children. It typically includes a combination of medications, lifestyle changes, and regular medical check-ups to control airway inflammation, prevent symptoms, and manage sudden attacks. The treatment aims to improve the child's quality of life and prevent complications associated with uncontrolled asthma.
Medications such as bronchodilators and corticosteroids are used to manage acute symptoms and prevent long-term lung damage. Inhaled corticosteroid is the preferred medication for controlling inflammation, as it has fewer side effects than oral steroids.
Lifestyle changes, such as avoiding triggers, improving air quality, and promoting physical activity, are also important components of asthma management. Development of new, targeted therapies and better adherence programs is an area of ongoing research and development in the field of asthma treatment in children.
The prevalence of pediatric asthma has increased globally over the past few decades, making it a significant public health concern. Early diagnosis along with proper treatment for asthma is essential to prevent long-term complications in children.
According to the Australian Institute for Health and Welfare, around 10.0% of children between the age of 0 and 14 years suffered from asthma in the country during 2017 to 2018. As per the World Health Organization (WHO), asthma affected around 262 million people globally and led to 4,55,000 deaths in 2019. Thus, increase in prevalence of pediatric asthma across the globe is anticipated to boost pediatric asthma treatment demand in the near future.
CDC’s National Asthma Control Program and asthma camps conducted by the Asthma Society of India offer quality of life for asthma patients through effective disease management techniques.
Environmental irritants such as smoke and air pollution can trigger asthma symptoms in children. Smoke from cigarettes, wood-burning stoves, and fireplaces can contain irritants that can inflame the airways and worsen asthma symptoms.
Similarly, air pollution and industrial emissions can also trigger asthma symptoms in kids. In order to minimize exposure to these triggers, it is recommended to avoid smoking indoors, reduce time spent in areas with high air pollution, and use air purifiers. It is also important to work with pediatricians to develop a comprehensive asthma management plan to minimize the frequency and severity of symptoms.
In terms of drug type, the global pediatric asthma treatment market has been classified into long-term control medications and quick-relief medications. The long-term control medications segment dominated the global market in 2021.
Long-term control medications, such as combination inhalers, are gaining traction due to their various benefits. Combination inhalers contain a corticosteroid and a bronchodilator. They help control asthma symptoms more effectively than using either medication alone.
Based on form, the global pediatric asthma treatment market has been segregated into inhalation/inhalers, solutions, pills, and injections. The inhalation/inhalers segment accounted for major share of the global market in 2021.
Inhalers can be a highly effective way to manage asthma symptoms. However, it is important to use them correctly. Inhalers can deliver the medication quickly and effectively. They are also compact and convenient to carry. This is estimated to bolster segment growth.
In terms of distribution channel, the market segmentation entails hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is likely to lead the industry in the near future. People prefer retail pharmacies, as they are convenient to purchase pediatric asthma medications.
North America is expected to dominate the global landscape during the forecast period. The market in North America is likely to expand at a high CAGR during the forecast period, owing to the high rate of incidence of pediatric asthma in the region.
According to the Center for Disease Control & Prevention (CDC), around 6 million children in the U.S. between the age of 0 and 17 are suffering from asthma. Various companies are carrying out innovations in treatment procedures, considering the high prevalence rate of pediatric asthma in the region. This is contributing to pediatric asthma treatment market growth in North America.
The pediatric asthma treatment market in Asia Pacific is anticipated to grow at a rapid pace during the forecast period. According to a study published in the Lung India journal, with an estimated 1.5 crore to 2 crore asthma patients, at least 1 in every 10 asthma patients globally is from India. Furthermore, up to 40.0% of children have a wheeze, which is termed asthma, at some point. Increase in focus on respiratory disease management and rise in awareness about managing pediatric asthma are fueling market expansion in the region.
The global pediatric asthma treatment market is fragmented, with the presence of large number of local as well as international players. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading companies.
Key players of the pediatric asthma treatment industry are ECU Health, AstraZeneca PLC, GlaxoSmithKline, CHIESI Farmaceutici S.p.A., Pfizer Inc., Sanofi, Novartis AG, OPKO Health, Inc., Boehringer Ingelheim International GmbH, and Teva Pharmaceutical Industries Ltd.
Each of these players has been profiled in the pediatric asthma treatment market report based on parameters such as financial overview, business segments, company overview, recent developments, product portfolio, and business strategies.
|
Attribute |
Detail |
|
Market Size Value in 2022 |
US$ 11.2 Bn |
|
Market Forecast Value in 2031 |
US$ 14.4 Bn |
|
Growth Rate (CAGR) |
2.9% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 11.2 Bn in 2022
It is projected to reach more than US$ 14.4 Bn by 2031
The CAGR is anticipated to be 2.9% from 2023 to 2031
Rise in incidence of asthma in children and increase in environmental irritants
North America is expected to account for the largest share during the forecast period
ECU Health, AstraZeneca PLC, GlaxoSmithKline, CHIESI Farmaceutici S.p.A., Pfizer Inc., Sanofi, Novartis AG, OPKO Health, Inc., Boehringer Ingelheim International GmbH, and Teva Pharmaceutical Industries Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Pediatric Asthma Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pediatric Asthma Treatment Market Analysis and Forecast, 2017- 2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Key product/brand Analysis
5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Pediatric Asthma Treatment Market Analysis and Forecast, By Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Type, 2017- 2031
6.3.1. Long-term Control Medications
6.3.1.1. Corticosteroids
6.3.1.2. Leukotriene Modifiers
6.3.1.3. Combination Inhalers
6.3.1.4. Theophylline
6.3.1.5. Others
6.3.2. Quick-relief Medications
6.3.2.1. Short-acting Beta Agonists
6.3.2.2. Others
6.4. Market Attractiveness By Drug Type
7. Global Pediatric Asthma Treatment Market Analysis and Forecast, By Form
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Form, 2017- 2031
7.3.1. Inhalation/Inhalers
7.3.1.1. Metered-dose Inhalers
7.3.1.2. Dry Powder Inhalers
7.3.2. Solutions (Liquids that can be used in nebulizers)
7.3.3. Pills
7.3.4. Injections
7.4. Market Attractiveness By Form
8. Global Pediatric Asthma Treatment Market Analysis and Forecast, By Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Distribution Channel, 2017- 2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness By Distribution Channel
9. Global Pediatric Asthma Treatment Market Analysis and Forecast, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Pediatric Asthma Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Drug Type, 2017- 2031
10.2.1. Long-term Control Medications
10.2.1.1. Corticosteroids
10.2.1.2. Leukotriene Modifiers
10.2.1.3. Combination Inhalers
10.2.1.4. Theophylline
10.2.1.5. Others
10.2.2. Quick-relief Medications
10.2.2.1. Short-acting Beta Agonists
10.2.2.2. Others
10.3. Market Value Forecast By Form, 2017- 2031
10.3.1. Inhalation/Inhalers
10.3.1.1. Metered-dose Inhalers
10.3.1.2. Dry Powder Inhalers
10.3.2. Solutions (Liquids that can be used in nebulizers)
10.3.3. Pills
10.3.4. Injections
10.4. Market Value Forecast By Distribution Channel, 2017- 2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast By Country, 2017- 2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Type
10.6.2. By Form
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Pediatric Asthma Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Type, 2017- 2031
11.2.1. Long-term Control Medications
11.2.1.1. Corticosteroids
11.2.1.2. Leukotriene Modifiers
11.2.1.3. Combination Inhalers
11.2.1.4. Theophylline
11.2.1.5. Others
11.2.2. Quick-relief Medications
11.2.2.1. Short-acting Beta Agonists
11.2.2.2. Others
11.3. Market Value Forecast By Form, 2017- 2031
11.3.1. Inhalation/Inhalers
11.3.1.1. Metered-dose Inhalers
11.3.1.2. Dry Powder Inhalers
11.3.2. Solutions (Liquids that can be used in nebulizers)
11.3.3. Pills
11.3.4. Injections
11.4. Market Value Forecast By Distribution Channel, 2017- 2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast By Country/Sub-region, 2017- 2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Type
11.6.2. By Form
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Pediatric Asthma Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Type, 2017- 2031
12.2.1. Long-term Control Medications
12.2.1.1. Corticosteroids
12.2.1.2. Leukotriene Modifiers
12.2.1.3. Combination Inhalers
12.2.1.4. Theophylline
12.2.1.5. Others
12.2.2. Quick-relief Medications
12.2.2.1. Short-acting Beta Agonists
12.2.2.2. Others
12.3. Market Value Forecast By Form, 2017- 2031
12.3.1. Inhalation/Inhalers
12.3.1.1. Metered-dose Inhalers
12.3.1.2. Dry Powder Inhalers
12.3.2. Solutions (Liquids that can be used in nebulizers)
12.3.3. Pills
12.3.4. Injections
12.4. Market Value Forecast By Distribution Channel, 2017- 2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast By Country/Sub-region, 2017- 2031
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Type
12.6.2. By Form
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Pediatric Asthma Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Type, 2017- 2031
13.2.1. Long-term Control Medications
13.2.1.1. Corticosteroids
13.2.1.2. Leukotriene Modifiers
13.2.1.3. Combination Inhalers
13.2.1.4. Theophylline
13.2.1.5. Others
13.2.2. Quick-relief Medications
13.2.2.1. Short-acting Beta Agonists
13.2.2.2. Others
13.3. Market Value Forecast By Form, 2017- 2031
13.3.1. Inhalation/Inhalers
13.3.1.1. Metered-dose Inhalers
13.3.1.2. Dry Powder Inhalers
13.3.2. Solutions (Liquids that can be used in nebulizers)
13.3.3. Pills
13.3.4. Injections
13.4. Market Value Forecast By Distribution Channel, 2017- 2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast By Country/Sub-region, 2017- 2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Type
13.6.2. By Form
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Pediatric Asthma Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Drug Type, 2017- 2031
14.2.1. Long-term Control Medications
14.2.1.1. Corticosteroids
14.2.1.2. Leukotriene Modifiers
14.2.1.3. Combination Inhalers
14.2.1.4. Theophylline
14.2.1.5. Others
14.2.2. Quick-relief Medications
14.2.2.1. Short-acting Beta Agonists
14.2.2.2. Others
14.3. Market Value Forecast By Form, 2017- 2031
14.3.1. Inhalation/Inhalers
14.3.1.1. Metered-dose Inhalers
14.3.1.2. Dry Powder Inhalers
14.3.2. Solutions (Liquids that can be used in nebulizers)
14.3.3. Pills
14.3.4. Injections
14.4. Market Value Forecast By Distribution Channel, 2017- 2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast By Country/Sub-region, 2017- 2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Type
14.6.2. By Form
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2022)
15.3. Company Profiles
15.3.1. AstraZeneca PLC
15.3.1.1. Company Overview
15.3.1.2. Drug Type Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. Boehringer Ingelheim International GmbH
15.3.2.1. Company Overview
15.3.2.2. Drug Type Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Strategic Overview
15.3.3. CHIESI Farmaceutici S.p.A.
15.3.3.1. Company Overview
15.3.3.2. Drug Type Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Strategic Overview
15.3.4. ECU Health
15.3.4.1. Company Overview
15.3.4.2. Drug Type Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Strategic Overview
15.3.5. GlaxoSmithKline
15.3.5.1. Company Overview
15.3.5.2. Drug Type Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Strategic Overview
15.3.6. Novartis AG
15.3.6.1. Company Overview
15.3.6.2. Drug Type Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Strategic Overview
15.3.7. OPKO Health, Inc.
15.3.7.1. Company Overview
15.3.7.2. Drug Type Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Strategic Overview
15.3.8. Pfizer Inc.
15.3.8.1. Company Overview
15.3.8.2. Drug Type Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Strategic Overview
15.3.9. Sanofi
15.3.9.1. Company Overview
15.3.9.2. Drug Type Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
15.3.10. Teva Pharmaceutical Industries Ltd.
15.3.10.1. Company Overview
15.3.10.2. Drug Type Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Strategic Overview
List of Tables
Table 01: Global Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 02: Global Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Form, 2017‒2031
Table 03: Global Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
Table 04: Global Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 07: North America Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Form, 2017‒2031
Table 08: North America Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
Table 09: Europe Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 10: Europe Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 11: Europe Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Form, 2017‒2031
Table 12: Europe Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
Table 13: Asia Pacific Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 15: Asia Pacific Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Form, 2017‒2031
Table 16: Asia Pacific Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
Table 17: Latin America Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 19: Latin America Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Form, 2017‒2031
Table 20: Latin America Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017‒2031
Table 23: Middle East & Africa Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Form, 2017‒2031
Table 24: Middle East & Africa Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel 2017–2031
List of Figures
Figure 01: Global Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Pediatric Asthma Treatment Market Value Share, by Drug Type, 2021
Figure 03: Pediatric Asthma Treatment Market Value Share, by Form, 2021
Figure 04: Pediatric Asthma Treatment Market Value Share, by Distribution Channel, 2021
Figure 05: Pediatric Asthma Treatment Market Value Share, by Region, 2021
Figure 06: Global Pediatric Asthma Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 07: Global Pediatric Asthma Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 08: Global Pediatric Asthma Treatment Market Value (US$ Mn), by Long-term Control Medications, 2017‒2031
Figure 09: Global Pediatric Asthma Treatment Market Value (US$ Mn), by Corticosteroids, 2017‒2031
Figure 10: Global Pediatric Asthma Treatment Market Value (US$ Mn), by Leukotriene Modifiers, 2017‒2031
Figure 11: Global Pediatric Asthma Treatment Market Value (US$ Mn), by Combination Inhalers, 2017‒2031
Figure 12: Global Pediatric Asthma Treatment Market Value (US$ Mn), by Theophylline, 2017‒2031
Figure 13: Global Pediatric Asthma Treatment Market Value (US$ Mn), by Others 2017‒2031
Figure 14: Global Pediatric Asthma Treatment Market Value (US$ Mn), by Quick-relief Medications 2017‒2031
Figure 15: Global Pediatric Asthma Treatment Market Value (US$ Mn), by Short-acting Beta Agonists 2017‒2031
Figure 16: Global Pediatric Asthma Treatment Market Value (US$ Mn), by Others 2017‒2031
Figure 17: Global Pediatric Asthma Treatment Market Value Share Analysis, by Form, 2021 and 2031
Figure 18: Global Pediatric Asthma Treatment Market Attractiveness Analysis, by Form, 2022–2031
Figure 19: Global Pediatric Asthma Treatment Market Value (US$ Mn), by Inhalation/Inhalers, 2017‒2031
Figure 20: Global Pediatric Asthma Treatment Market Value (US$ Mn), by Solution, 2017‒2031
Figure 21: Global Pediatric Asthma Treatment Market Value (US$ Mn), by Pills, 2017‒2031
Figure 22: Global Pediatric Asthma Treatment Market Value (US$ Mn), by Injections, 2017‒2031
Figure 23: Global Pediatric Asthma Treatment Market Value Share Analysis, by Distribution Channel 2021 and 2031
Figure 24: Global Pediatric Asthma Treatment Market Attractiveness Analysis, by Distribution Channel 2022–2031
Figure 25: Global Pediatric Asthma Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031
Figure 26: Global Pediatric Asthma Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 27: Global Pediatric Asthma Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031
Figure 28: Global Pediatric Asthma Treatment Market Value Share Analysis, by Region, 2021 and 2031
Figure 29: Global Pediatric Asthma Treatment Market Attractiveness Analysis, by Region, 2022–2031
Figure 30: North America Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 31: North America Pediatric Asthma Treatment Market Value Share Analysis, by Country, 2021 and 2031
Figure 32: North America Pediatric Asthma Treatment Market Attractiveness Analysis, by Country, 2022–2031
Figure 33: North America Pediatric Asthma Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 34: North America Pediatric Asthma Treatment Market Attractiveness Analysis, by Drug Type 2022–2031
Figure 35: North America Pediatric Asthma Treatment Market Value Share Analysis, by Form, 2021 and 2031
Figure 36: North America Pediatric Asthma Treatment Market Attractiveness Analysis, by Form 2022–2031
Figure 37: North America Pediatric Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 38: North America Pediatric Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 39: Europe Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 40: Europe Pediatric Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 41: Europe Pediatric Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 42: Europe Pediatric Asthma Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 43: Europe Pediatric Asthma Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 44: Europe Pediatric Asthma Treatment Market Value Share Analysis, by Form, 2021 and 2031
Figure 45: Europe Pediatric Asthma Treatment Market Attractiveness Analysis, by Form, 2022–2031
Figure 46: Europe Pediatric Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 47: Europe Pediatric Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 48: Asia Pacific Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 49: Asia Pacific Pediatric Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 50: Asia Pacific Pediatric Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 51: Asia Pacific Pediatric Asthma Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 52: Asia Pacific Pediatric Asthma Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 53: Asia Pacific Pediatric Asthma Treatment Market Value Share Analysis, by Form, 2021 and 2031
Figure 54: Asia Pacific Pediatric Asthma Treatment Market Attractiveness Analysis, by Form, 2022–2031
Figure 55: Asia Pacific Pediatric Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 56: Asia Pacific Pediatric Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 57: Latin America Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 58: Latin America Pediatric Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 59: Latin America Pediatric Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 60: Latin America Pediatric Asthma Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 61: Latin America Pediatric Asthma Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 62: Latin America Pediatric Asthma Treatment Market Value Share Analysis, by Form, 2021 and 2031
Figure 63: Latin America Pediatric Asthma Treatment Market Attractiveness Analysis, by Form, 2022–2031
Figure 64: Latin America Pediatric Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 65: Latin America Pediatric Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 66: Middle East & Africa Pediatric Asthma Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 67: Middle East & Africa Pediatric Asthma Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 68: Middle East & Africa Pediatric Asthma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 69: Middle East & Africa Pediatric Asthma Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 70: Middle East & Africa Pediatric Asthma Treatment Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 71: Middle East & Africa Pediatric Asthma Treatment Market Value Share Analysis, by Form, 2021 and 2031
Figure 72: Middle East & Africa Pediatric Asthma Treatment Market Attractiveness Analysis, by Form, 2022–2031
Figure 73: Middle East & Africa Pediatric Asthma Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 74: Middle East & Africa Pediatric Asthma Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 75: Company Share Analysis
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pediatric Asthma Treatment Market
